Matthew B. Yurgelun, MD, discusses a study that determined that nearly 10% of patients with colorectal cancer had germline cancer susceptibility gene mutations and its implications for patients and their families.
The international CanStem303C trial is evaluating the combination of napabucasin, the most advanced cancer stemness inhibitor in development, with FOLFIRI chemotherapy in patients with previously treated metastatic colorectal cancer.
John L. Marshall, MD, discusses the results of the CALGB 80405 trial and other ongoing efforts to determine the underlying molecular basis for the sidedness issue in colorectal cancer.
Manish Shah, MD, discusses ongoing efforts to understand the distinction between early-onset CRC and traditional CRC.
A dual attack on HER2 expression resulted in a 30% objective response rate in heavily pretreated patients with HER2-positive metastatic colorectal cancer.
Andrew Kennedy, MD, speaks on the various approaches used in clinical practice to treat patients who have colorectal cancer with liver metastases.
Brian Hemphill, MD, provides insight on some of the challenges currently being faced in gastrointestinal malignancies and how molecular profiles of tumors will dramatically change outcomes for these patients.
Bert O'Neil, MD, discusses the need for novel treatments for patients with metastatic colorectal cancer as well as why researchers need to develop a deeper understanding of tumor biology.
A supplemental biologics license application for pembrolizumab (Keytruda) for previously treated patients with advanced microsatellite instability-high cancer remains under review by the FDA.
Arturo Loaiza-Bonilla, MD, discusses the potential role of BRAF and CTNNB1 mutations in the survival difference between colorectal cancer patients with left- and right-sided tumors.